Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganetespib plus docetaxel versus docetaxel in advanced NSCLC adenocarcinoma
NL-OMON41451Phase 3Active, not recruiting
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Aug 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ganetespib and docetaxel in Non-small cell lung cancer adenocarcinoma (NSCLC) and non-small cell lung cancer (NSCLC), sponsored by Synta Pharmaceuticals Corp. Started Aug 2014; status: active, not recruiting.
02
Drugs
ganetespibdocetaxel
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON41451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41451.